Bio-Techne to Be Acquired by Merck for $73 Per Share in All-Cash MergerTradingView·8 hours agoTECH+51.00%MRK
This Stock Has Already Doubled This Year and Is Still Racing Towards a Major CatalystMotley Fool·13 hours agoMRNA+9.92%MRNX+21.42%
Jefferies raised the target price for Moderna from $45 to $53Zhitong·14 hours agoMRNA+9.92%MRNX+21.42%
Moderna CEO Says He’s Cautiously Optimistic on Flu Vaccine ApprovalCoinLive·1 day ago, 01:37 PMMRNA+9.92%MRNX+21.42%
Bio-Techne retention bonuses approved for Kim Kelderman, Jim HippelTradingView·8 hours agoTECH+51.00%
Merck acquires Bio-Techne for a premium of $11.3 billion, pre-market jumps 20%Zhitong·1 day ago, 06:46 AMTECH+51.00%MRK
Vertex Pharmaceuticals (VRTX) Following Fresh CASGEVY Data Has Its Valuation Back In FocusSimplywall·2 hours agoVRTX+2.42%
Bio-Techne Corp Stock 12‑Month Price Target Raised to $66.42, Implies 13% UpsideTradingView·23 hours agoTECH+51.00%
Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution RisksTip Ranks·6 hours agoMRNA+9.92%MRK+1.38%
Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseasesPUBT·1 day ago, 06:20 AMMRNA+9.92%MRNX+21.42%
Merck KGaA Group has agreed to acquire Bio-Techne for $73 per share in cashWallstreetcn·1 day ago, 04:37 AMTECH+51.00%MRK
Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% DownsideTradingView·20 hours agoMRNA+9.92%MRNX+21.42%
